AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 1568660
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid (UDCA, 12 mg/kg/day)
Trial: 1568660
Drug: Chenodeoxycholic acid
RxNorm normalized name: Chenodeoxycholic acid
DrugBank: Chenodeoxycholic acid (DB06777)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chenodeoxycholic acid (CDCA, 12 mg/kg/day)
Trial: 1568660
Drug: Bedtime administration
RxNorm normalized name: Buckley's Bedtime Formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bedtime administration of UDCA
Trial: 1568660
Drug: Mealtime administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mealtime administration of UDCA
Trial: 1568660
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (CDCA 6 mg/kg/day + UDCA 6 mg/kg/day at bedtime)
Trial: 30526264
Drug: Scopolamine patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scopolamine patch
Trial: 24706493
Drug: Fesoterodine 4
RxNorm normalized name: fesoterodine 4 mg oral tablet, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fesoterodine 4 to 8 mg
Trial: 22120090
Drug: Tolvaptan 15-120
RxNorm normalized name: tolvaptan 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolvaptan 15-120 mg single dose
Trial: 22120090
Drug: Tolvaptan 30-120
RxNorm normalized name: tolvaptan 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolvaptan 30-120 mg once daily for 7 days
Trial: 22120090
Drug: Tolvaptan 60
RxNorm normalized name: tolvaptan 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolvaptan 60 mg and above
Trial: 18219850
Drug: Trastuzumab alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trastuzumab alone therapy (A-group)
Trial: 18219850
Drug: Trastuzumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trastuzumab plus taxane therapy (B-group)
Trial: 18219850
Drug: Trastuzumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trastuzumab plus taxane therapy (after addition to A-group)
Trial: 3605748
Drug: Thiopental treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiopental treatment (EEG suppression)
Trial: 3605748
Drug: Isoflurane treatment
RxNorm normalized name: Isoflurane
DrugBank: Isoflurane (DB00753)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isoflurane treatment (EEG suppression)
Trial: 28672405
Drug: Long-term antidepressant
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term antidepressant treatment (SSRI/SNRI) for 6-52 weeks
Trial: 28672405
Drug: No antidepressant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antidepressant treatment (with or without benzodiazepine medication)
Trial: 25537835
Drug: Diluted insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diluted insulin aspart (20 U/ml)
Trial: 25537835
Drug: Standard insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard insulin aspart (100 U/ml)
Trial: 22084206
Drug: Standard CTPA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard CTPA (100-120 kVp) with standard contrast medium injection (n = 46)
Trial: 20815182
Drug: Recovery sleep
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recovery sleep doses of 0, 2, 4, 6, 8, or 10 h TIB after 5 nights of sleep restriction to 4 h TIB
Trial: 19083445
Drug: BTE tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BTE tablets (333 mg)
Trial: 12785023
Drug: High-dose sclerotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose sclerotherapy (Group B)
Trial: 10716475
Drug: Candesartan cilexetil
RxNorm normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Candesartan cilexetil (Ang II type 1 receptor antagonist)
Trial: 29525929
Drug: Perceived need
RxNorm normalized name: diphenhydramine
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Perceived need for treatment
Trial: 24514907
Drug: High-intensity exercise
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-intensity exercise training with 250 mg resveratrol
Trial: 24514907
Drug: Resveratrol (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resveratrol (250 mg)
Trial: 22395588
Drug: 5% dexpanthenol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% dexpanthenol (DT) ointment
Trial: 22395588
Drug: 1% hydrocortisone
RxNorm normalized name: HYDROCORTISONE 0.01 g in 1 g TOPICAL OINTMENT [AFASSCO 1% Hydrocortisone]
DrugBank: Hydrocortisone (DB00741)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1% hydrocortisone (HC) ointment
Trial: 20808314
Drug: Siltuximab 3
RxNorm normalized name: Siltuximab
DrugBank: Siltuximab (DB09036)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Siltuximab 3 mg/kg, q3w × 4
Trial: 20808314
Drug: Siltuximab 6
RxNorm normalized name: Siltuximab
DrugBank: Siltuximab (DB09036)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Siltuximab 6 mg/kg, q3w × 4
Trial: 20808314
Drug: Siltuximab 6
RxNorm normalized name: Siltuximab
DrugBank: Siltuximab (DB09036)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Siltuximab 6 mg/kg, q2w × 6
Trial: 19025059
Drug: Estalin 2
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Estalin 2 mg tablets (test formulation)
Trial: 19025059
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg tablets of the originator product (reference formulation)
Trial: 15998754
Drug: Combination antiretroviral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination antiretroviral regimens, elective cesarean section in selected patients, avoidance of breastfeeding
Trial: 12841803
Drug: Exposure to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure to direct-to-consumer advertisements for osteoporosis drugs
Trial: 11815322
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (10 mg elemental Zn/d in cherry syrup)
Trial: 11815322
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (cherry syrup alone)
Trial: 8775955
Drug: Direct referral
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct referral to oral and maxillofacial surgery
Trial: 2139283
Drug: 40 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 micrograms dose, 4 dose vaccination schedule
Trial: 2139283
Drug: 40 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 micrograms dose, 3 dose vaccination schedule
Trial: 2139283
Drug: 40 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 micrograms dose, 0, 1, 2, 6 month schedule
Trial: 2139283
Drug: 40 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 micrograms dose, 0, 1, 2, 12 month schedule
Trial: 2139283
Drug: 20 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 micrograms dose
Trial: 7018854
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg Ro 13-9904
Trial: 7018854
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg Ro 13-9904
Trial: 7018854
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg tobramycin
Trial: 6368877
Drug: Acyclovir (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acyclovir (200 mg) five times daily for five days
Trial: 24906976
Drug: Metformin (M)
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin (M) 2 g/day
Trial: 24906976
Drug: Metformin (M)
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin (M) 2 g/day + Oral contraceptive pills (OCP) (150 mg desogestrel + 30 microgram ethinylestradiol)
Trial: 10905421
Drug: Abuse-focused cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abuse-focused cognitive behavioral therapy
Trial: 2408515
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg t.i.d. tritoqualine for three days
Trial: 2408515
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg t.i.d. tritoqualine for three days (in patients with a history of allergy)
Trial: 25641662
Drug: Sunitinib (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib (50 mg daily in 6-week cycles: 4 weeks on treatment, 2 weeks off treatment)
Trial: 27094801
Drug: Pregabalin with
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pregabalin with sham treatment
Trial: 12859466
Drug: Saline 1
RxNorm normalized name: normal saline 10 mL Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline 1 ml.kg‐1 (group S)
Trial: 6209900
Drug: Meclosorb cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meclosorb cream
Trial: 6209900
Drug: Tetracycline tablets
RxNorm normalized name: Oxytetracycline Tablets
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tetracycline tablets (500 mg daily)
Trial: 21401662
Drug: Functional Electrical
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Functional Electrical Stimulation (FES) therapy
Trial: 14666739
Drug: Oral-B CrossAction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral-B CrossAction Power
Trial: 8839728
Drug: Oral exhaled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral exhaled NO in asthmatic children
Trial: 8839728
Drug: Oral exhaled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral exhaled NO in healthy controls
Trial: 8839728
Drug: Correlation between
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Correlation between oral exhaled NO and FeV1
Trial: 8839728
Drug: Correlation between
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Correlation between oral/nasal exhaled NO and other markers
Trial: 22157100
Drug: Intra-articular dexamethasone
RxNorm normalized name: dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-articular dexamethasone administration after arthrocentesis
Trial: 22157100
Drug: Saline (placebo)
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline (placebo) administration after arthrocentesis
Trial: 19751247
Drug: Prucalopride 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prucalopride 0.5 mg once daily for 28 days
Trial: 19751247
Drug: Prucalopride 1
RxNorm normalized name: prucalopride 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prucalopride 1 mg once daily for 28 days
Trial: 19751247
Drug: Prucalopride 2
RxNorm normalized name: prucalopride 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prucalopride 2 mg once daily for 28 days
Trial: 2124179
Drug: Levonorgestrel 20
RxNorm normalized name: ethinyl estradiol-levonorgestrel 20 mcg-90 mcg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levonorgestrel 20 mcg/day (LNg 20)
Trial: 400246
Drug: Therapist-conducted, face-to-face
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapist-conducted, face-to-face progressive, deep-muscle relaxation training for 10 weekly sessions
Trial: 400246
Drug: Progressive deep-muscle
RxNorm normalized name: Deep Sea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progressive deep-muscle relaxation therapy conducted mainly by home use of audio cassettes
Trial: 400246
Drug: Nonspecific individual
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nonspecific individual psychotherapy for 10 weekly sessions
Trial: 26158794
Drug: Co-administration of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-administration of tofogliflozin and anti-T2DM drugs
Trial: 26158794
Drug: Anti-T2DM drugs
RxNorm normalized name: anti-CD11a
DrugBank: Efalizumab (DB00095)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Anti-T2DM drugs alone
Trial: 19539103
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 30 mg duloxetine
Trial: 19539103
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 60 mg duloxetine
Trial: 19539103
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 90 mg duloxetine
Trial: 19539103
Drug: Multiple doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses of 30 mg duloxetine (twice daily for 7 days)
Trial: 15261565
Drug: Methylprednisolone (MP)
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (MP) once monthly for 6 months
Trial: 3896288
Drug: First line
RxNorm normalized name: ALCOHOL 0.75 mL in 1 mL TOPICAL CLOTH [First Line Alcohol Wipes]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First line therapy (Melphalan and Prednisone)
Trial: 3896288
Drug: Continuation of
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuation of first line therapy for a further year
Trial: 29215971
Drug: Mediterranean-style diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mediterranean-style diet (MedDiet) supplemented with fish oil, received fortnightly food hampers and MedDiet cooking workshops for 3 months and fish oil supplements for 6 months
Trial: 22173041
Drug: Daily mild
RxNorm normalized name: Octinoxate 3.50 g in 50 mL / Homosalate 3.00 g in 50 mL / Octisalate 2.25 g in 50 mL TOPICAL CREAM [VILLAGE11FACTORY DAILY MILD SUN]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily mild home exercises (calisthenics focusing on balance-control, low-back-connected musculature) for 15 minutes daily over 2 months
Trial: 20202636
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg Mycophenolate mofetil (MMF) BD for at least 2 weeks
Trial: 12232562
Drug: Venoruton (HR)
DrugBank: Oxerutins (DB15826)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venoruton (HR) 2 g/day for 8 weeks
Trial: 12232562
Drug: Daflon (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daflon (500 mg) three tablets daily every 8 hours
Trial: 10091293
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (5000 U anti-Xa; Fragmin P forte) s.c.
Trial: 10091293
Drug: Dose-adjusted coumarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-adjusted coumarin (Marcumar) p.o.
Trial: 7471600
Drug: Atenolol 50
RxNorm normalized name: atenolol 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol 50 mg, 100 mg, 200 mg
Trial: 7471600
Drug: Sotalol 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sotalol 50 mg, 100 mg, 200 mg
Trial: 7471600
Drug: Metoprolol 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol 400 mg
Trial: 7471600
Drug: Metoprolol 50
RxNorm normalized name: metoprolol 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol 50 mg, 100 mg, 200 mg
Trial: 27888578
Drug: UltraBLOX™ radiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UltraBLOX™ radiation attenuating hand cream
Trial: 24119605
Drug: Triamcinolone (TA)
RxNorm normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triamcinolone (TA) 20 mg-soaked bioabsorbable dressing
Trial: 19634512
Drug: Iron(III) hydroxide
RxNorm normalized name: Iron(III) hydroxide sucrose complex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron(III) hydroxide polymaltose complex (IPC, Maltofer) containing 100 mg of elemental iron, 6 days a week for 8 months
Trial: 11133598
Drug: DCLHb (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DCLHb (1 g/kg)
Trial: 11133598
Drug: DCLHb (936
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DCLHb (936 +/- 276 mg/kg)
Trial: 9926153
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose allergen exposure (individualised to 25% of the total dose causing immediate and late response)
Trial: 9926153
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose allergen exposure
Trial: 23105144
Drug: 180 μg/week
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 180 μg/week Pegylated interferon alfa-2a
Trial: 23105144
Drug: 90 μg/week
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 μg/week Pegylated interferon alfa-2a
Trial: 23105144
Drug: Sustained viral
RxNorm normalized name: Sustain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained viral load <400 copies/mL
Trial: 21320217
Drug: Music therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music therapy (listening to selected music from the evening before surgery to the second day after surgery)
Trial: 18181909
Drug: RELIANCE G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RELIANCE G leads
Trial: 16644332
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 600 mg BID x 4 doses plus hydration
Trial: 16644332
Drug: Hydration alone
RxNorm normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydration alone (combined oral and rapid intravenous hydration)
Trial: 12804346
Drug: Antiretroviral agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiretroviral agent prescription
Trial: 10644538
Drug: Glucose (1
RxNorm normalized name: Fludeoxyglucose (18F)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glucose (1 g/kg body mass)
Trial: 10644538
Drug: Sucrose (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucrose (1 g/kg body mass)
Trial: 8888809
Drug: Idarubicin (IDR)
DrugBank: Idarubicin (DB01177)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Idarubicin (IDR) 12.5 mg/m2/week x 3
Trial: 8888809
Drug: Idarubicin (IDR)
DrugBank: Idarubicin (DB01177)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Idarubicin (IDR) 10 mg/m2/week x 3
Trial: 8888809
Drug: Daunomycin (DNR)
RxNorm normalized name: Daunomycin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Daunomycin (DNR) 45 mg/m2/week x 3
Trial: 8888809
Drug: Idarubicin (IDR)
DrugBank: Idarubicin (DB01177)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Idarubicin (IDR) 12.5 mg/m2
Trial: 8888809
Drug: Idarubicin (IDR)
DrugBank: Idarubicin (DB01177)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Idarubicin (IDR) 10 mg/m2
Trial: 1672229
Drug: Topical treatment
RxNorm normalized name: Hongo Killer Treatment Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical treatment with tretinoin
Trial: 1672229
Drug: Systemic treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Systemic treatment with etretinate
Trial: 6210278
Drug: cis‐DDP (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cis‐DDP (3 mg/kg iv day 1) and BLM (15‐20 mg iv continuously day 2‐6)
Trial: 6210278
Drug: MTX (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTX (30 mg/m2 iv day 1 + 6) and VDS (3 mg/m2 iv day 2 + 7)
Trial: 6210278
Drug: CR and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CR and PR achieved by surgery and/or x‐ray therapy
Trial: 28207840
Drug: Neuromuscular electrical
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Neuromuscular electrical stimulation for 20 min twice a day and 19 g of lupin protein supplementation
Trial: 24428805
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose multiple micronutrient supplementation
Trial: 22942294
Drug: Aspirin 100
RxNorm normalized name: aspirin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 100 mg plus clopidogrel 75 mg
Trial: 20620518
Drug: Initial arterial
RxNorm normalized name: Echinacea, aerial parts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial arterial revascularization (IAR) with rocuronium (1 mg/kg) infusion at 0.25 mg kg(‐1) h(‐1)
Trial: 20620518
Drug: Initial portal
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial portal revascularization (IPR) with rocuronium (1 mg/kg) infusion at 0.25 mg kg(‐1) h(‐1)
Trial: 17463219
Drug: Acetaminophen (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (1000 mg) administered 0 hours relative to pramlintide (120 microg)
Trial: 17463219
Drug: Acetaminophen (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (1000 mg) administered +1 hours relative to pramlintide (120 microg)
Trial: 17463219
Drug: Acetaminophen (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (1000 mg) administered +2 hours relative to pramlintide (120 microg)
Trial: 17463219
Drug: Acetaminophen (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (1000 mg) administered -2 hours relative to pramlintide (120 microg)
Trial: 17463219
Drug: Acetaminophen (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (1000 mg) administered -1 hours relative to pramlintide (120 microg)